To test for safety and prove that the Atrantil formulation was more than just a good idea, we have conducted two peer reviewed and published clinical studies.
In a double-blind clinical study of patients suffering from bloating, constipation and abdominal discomfort, Atrantíl proved to be more than 88 percent effective in relieving symptoms. The results of the study were published in the Journal of Gastroenterology and Hepatology Research – September 21, 2015 pp. 1762-1767.
The open-label study targeted the toughest-to-treat patients to illustrate the efficacy of Atrantíl. Before beginning the study, patients qualified to participate only after failing to find relief from at least four other therapies. The trial showed that 80 percent of patients found relief after using Atrantíl to control their bloating, constipation and abdominal discomfort. The results of the study were published in the World Journal of Gastrointestinal Pharmacology and Therapeutics – August 6, 2016 pp. 463-468.
We look forward to conducting more larger scale clinical trials in the future.